These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 9284572)
1. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors]. Sundblad AS; Caprarulo L Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572 [TBL] [Abstract][Full Text] [Related]
2. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue]. Schulze MH; Buchmann J Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188 [TBL] [Abstract][Full Text] [Related]
3. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors. Keshgegian AA Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626 [TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
5. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953 [TBL] [Abstract][Full Text] [Related]
7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596 [TBL] [Abstract][Full Text] [Related]
9. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Bhargava V; Kell DL; van de Rijn M; Warnke RA Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Briffod M; Hacène K; Le Doussal V Mod Pathol; 2000 Aug; 13(8):841-50. PubMed ID: 10955449 [TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors]. Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229 [TBL] [Abstract][Full Text] [Related]
12. Nuclear areas in breast cancer: relationship with estrogen and progesterone receptor expression. Maiorana A; Cavallari V; Bagni A; Ussia F; Maiorana MC; Fano RA Anal Cell Pathol; 1996 Aug; 11(3):199-209. PubMed ID: 8888955 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. Suthipintawong C; Wejaranayang C; Vipupinyo C J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508 [TBL] [Abstract][Full Text] [Related]
14. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477 [TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Wilbur DC; Barrows GH Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877 [TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Agoff SN; Swanson PE; Linden H; Hawes SE; Lawton TJ Am J Clin Pathol; 2003 Nov; 120(5):725-31. PubMed ID: 14608899 [TBL] [Abstract][Full Text] [Related]
18. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513 [TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129 [TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study. Marrazzo A; Taormina P; Leonardi P; Lupo F; Filosto S Anticancer Res; 1995; 15(2):521-6. PubMed ID: 7763033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]